OUP and Sofinnova Partners invested in 28-7 Therapeutics to take its series A round to $82.8m, enabling the Harvard spinout to pursue accelerated development of its cancer drug pipeline.
Twentyeight-Seven (28-7) Therapeutics, a US-based cancer drug development spinout of Harvard University, has extended its series A round to $82.8m with a $15m second tranche backed by spinout-focused investment firm Osage University Partners.
The extension was led by venture capital firm Sofinnova Partners and followed an initial $65m series A close in September 2018 co-led by investment firm MPM Capital and Novartis Venture Fund, the investment arm of pharmaceutical firm Novartis.
The original tranche also featured Johnson &…
